G1 Therapeutics/GTHX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About G1 Therapeutics

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.

Ticker

GTHX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

John Bailey

Employees

100

Headquarters

Research triangle park, United States

G1 Therapeutics Metrics

BasicAdvanced
$173M
Market cap
-
P/E ratio
-$0.61
EPS
1.71
Beta
-
Dividend rate
$173M
1.71378
$6.14
$1.08
1.3M
2.94
2.555
133.916
155.352
-3.31%
-23.18%
-84.13%
-30.95%
2.053
6.214
6.22
46.55%
77.85%
22.14%

What the Analysts think about G1 Therapeutics

Analyst Ratings

Majority rating from 6 analysts.
Buy

G1 Therapeutics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-70.83% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$14M
-2.70%
Net income
-$10M
-5.56%
Profit margin
-70.83%
-2.93%

G1 Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.72%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.14
-$0.35
-$0.21
-$0.20
-
Expected
-$0.22
-$0.33
-$0.28
-$0.21
-$0.17
Surprise
-164.00%
6.38%
-23.69%
-2.72%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for G1 Therapeutics stock?

G1 Therapeutics (GTHX) has a market cap of $173M as of June 15, 2024.

What is the P/E ratio for G1 Therapeutics stock?

The price to earnings (P/E) ratio for G1 Therapeutics (GTHX) stock is 0 as of June 15, 2024.

Does G1 Therapeutics stock pay dividends?

No, G1 Therapeutics (GTHX) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next G1 Therapeutics dividend payment date?

G1 Therapeutics (GTHX) stock does not pay dividends to its shareholders.

What is the beta indicator for G1 Therapeutics?

G1 Therapeutics (GTHX) has a beta rating of 1.71. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the G1 Therapeutics stock price target?

The target price for G1 Therapeutics (GTHX) stock is $8.5, which is NaN% below the current price of $. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell G1 Therapeutics stock

Buy or sell G1 Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing